Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients

Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA level...

Descripción completa

Detalles Bibliográficos
Autores: González-Sánchez, Marta|||0000-0001-9155-1438, Jiménez, Javier, Narváez García, Arantzazu|||0000-0001-8141-558X, Antequera, Desiree, Llamas-Velasco, Sara|||0000-0002-9174-2610, Herrero San-Martín, Alejandro, Molina Arjona, Jose Antonio, Lopez de Munain, Adolfo|||0000-0002-9509-4032, Lleó, Alberto|||0000-0002-2568-5478, Marco, María Pilar|||0000-0002-4064-1668, Rodríguez-Núñez, Montserrat, Pérez-Martínez, David Andrés|||0000-0001-5587-0415, Villarejo-Galende, Alberto|||0000-0002-6834-7620, Bartolome, Fernando|||0000-0001-9322-8933, Domínguez, Elena, Carro, Eva M.
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:283713
Acceso en línea:https://ddd.uab.cat/record/283713
https://dx.doi.org/urn:doi:10.3390/biom10040571
Access Level:acceso abierto
Palabra clave:Alzheimer's disease
Amyloid-β
Biomarkers
Cerebrospinal fluid
Kynurenine pathway
Tau protein
Descripción
Sumario:Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.

Similares en LA Referencia